Form 4: Amgen Director Greg Garland Acquires 809 Shares Through RSU Vesting

Amgen Inc. Director Greg C. Garland acquired 809 shares of common stock on May 23, 2025, through the immediate vesting of Restricted Stock Units, increasing his total beneficial ownership to 13,183 shares.

Summary

• Amgen Inc. Director Greg C. Garland acquired 809 shares of the company's common stock.
• The transaction occurred on May 23, 2025.
• The acquisition was a result of the immediate vesting of Restricted Stock Units (RSUs) granted at a price of $0 per share.
• These RSUs were granted under the Amgen Inc. 2009 Director Incentive Program, as amended, and the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.
• Following this transaction, Mr. Garland's total beneficial ownership of Amgen common stock stands at 13,183 shares.
• Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis and may be deferred by the director according to an elected deferral schedule.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates a director increasing their stake in the company, which generally aligns their interests with shareholders. This is a routine compensation event (vesting of RSUs) rather than an open market purchase, so the positive sentiment is not as strong as a direct cash purchase, but still favorable.

Positives

• Director Greg C. Garland increased his direct beneficial ownership in Amgen Inc. by 809 shares, aligning his interests further with shareholders.
• The acquisition through RSU vesting is a standard component of director compensation, reflecting ongoing commitment and incentivization.

Future Outlook

This Form 4 filing pertains to an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details a routine insider transaction, specifically the vesting of Restricted Stock Units (RSUs) for a director. Such equity-based compensation is a common practice across the biotechnology and pharmaceutical industry, including major players like Amgen, to align the interests of directors and executives with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a widely adopted practice among large-cap pharmaceutical and biotechnology companies, including peers such as Pfizer, Johnson & Johnson, and Merck.
• The immediate vesting of RSUs, as seen in this filing, is a common structure for director equity awards, although some companies may implement performance-based vesting or longer deferral periods.

Corporate Governance

Related Party Transactions

• Acquisition of 809 shares of common stock by Director Greg C. Garland through the vesting of Restricted Stock Units (RSUs) granted under the company's established equity incentive plans, representing a standard compensation transaction between the company and a related party (director).

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholders due to increased equity ownership.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Key Dates

Recommendation

Keywords

Amgen, AMGN, Form 4, Insider Transaction, Stock Acquisition, Director Compensation, Restricted Stock Units, RSU, Equity Incentive Plan